By comparing pre- and post-treatment tumors from patients with resectable NSCLC treated with NAC or NAPC, we were able to further address the underlying mechanisms by which PD-1 blockade augments the efficacy of chemotherapy. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.